Synthesis and structure-activity studies on N-[5-(1H-imidazol-4-yl)-5,6,7,8-tetrahydro-1-naphthalenyl]methanesulfonamide, an imidazole-containing α1A-adrenoceptor agonist

Journal of Medicinal Chemistry

Volumn 47, Issue 12, 2004, Pages 3220-3235

  Altenbach, Robert J ^a   Khilevich, Albert ^a,b   Kolasa, Teodozyj ^a   Rohde, Jeffrey J ^a   Bhatia, Pramila A ^a   Patel, Meena V ^a   Searle, Xenia B ^a   Yang, Fan ^a,c   Bunnelle, William H ^a   Tietje, Karin ^a   Bayburt, Erol K ^a   Carroll, William A ^a   Meyer, Michael D ^a   Henry, Rodger ^a   Buckner, Steven A ^a   Kuk, Jane ^a   Daza, Anthony V ^a   Milicic, Ivan V ^a   Cain, John C ^a   Kang, Chae H ^a   Ireland, Lynne M ^a,b   Carr, Tracy L ^a   Miller, Thomas R ^a   Hancock, Arthur A ^a   Nakane, Masaki ^a   Esbenshade, Timothy A ^a   Brune, Michael E ^a   O'Neill, Alyssa B ^a   Gauvin, Donna M ^a   Katwala, Sweta P ^a   Holladay, Mark W ^a,d   Brioni, Jorge D ^a   Sullivan, James P ^a   more..

^a ABBOTT LABORATORIES   (United States)

^b PFIZER INC   (United States)

^c Novartis   (United States)

^d SIDDCO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 1 (2,5 DIMETHOXYPHENYL)ETHANOL; ALPHA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 1A ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA 1B ADRENERGIC RECEPTOR; ALPHA 1D ADRENERGIC RECEPTOR; ALPHA 2A ADRENERGIC RECEPTOR; ALPHA 2B ADRENERGIC RECEPTOR; IMIDAZOLE DERIVATIVE; N [5 (1H IMIDAZOL 4 YL) 5,6,7,8 TETRAHYDRO 1 NAPHTHALENYL]METHANESULFONAMIDE; PHENYLPROPANOLAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA; ARTICLE; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; DOG; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG SYNTHESIS; MEAN ARTERIAL PRESSURE; NONHUMAN; PROSTATE; RABBIT; RAT; RECEPTOR AFFINITY; SMOOTH MUSCLE CONTRACTILITY; SMOOTH MUSCLE TONE; SPLEEN; STRUCTURE ACTIVITY RELATION; URETHRA;

ANIMALS; AORTA; BLOOD PRESSURE; DOGS; FEMALE; IMIDAZOLES; MALE; MUSCLE CONTRACTION; MUSCLE, SMOOTH; NAPHTHALENES; RABBITS; RADIOLIGAND ASSAY; RATS; RECEPTORS, ADRENERGIC, ALPHA-1; SPLEEN; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; TETRAHYDRONAPHTHALENES; URETHRA; VAS DEFERENS;

EID: 2542587862     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030551a     Document Type: Article

References (75)

1. 1A adrenoceptor agonists. Abstr. Pap.-Am. Chem. Soc. 2000, MEDI-293.
2. Andersson, K. E. Pharmacology of Lower Urinary Tract Smooth Muscles and Penile Erectile Tissues. Pharmacol. Rev. 1993, 45, 253-308.
3. Collste, L.; Lindskog, M. Phenylpropanolamine in treatment of female stress urinary incontinence. Double-blind placebo controlled study in 24 patients. Urology 1987, 30, 398-403.
4. (a) Jonas, D. Treatment of Female Stress Incontinence with Midodrine: Preliminary Report. J. Urol. 1977, 118, 980-982.
5. (b) Garofalo, F.; Lalanne, G. M.; Nanni, G. Midodrine for Female Incontinence: A Preliminary Report. Clin. Ther. 1986, 9, 44-46.
6. (c) Nito, H. Clinical effect of midodrine hydrochloride on the patients with urinary incontinence. Hinyokika Kiyo 1994, 40, 91-94.
7. (d) Weil, E. H.; Eerdmans, P. H.; Dijkman, G. A.; Tamussino, K.; Feyereisl, J.; Vierhout, M. E.; Schmidbauer, C.; Egarter, C.; Kolle, D.; Plasman, J. E.; Heidler, H.; Abbuhl, B. E.; Wein, W. Randomized Double-Blind Placebo-Controlled Multicenter Evaluation of Efficacy and Dose Finding of Midodrine Hydrochloride in Women with Mild to Moderate Stress Urinary Incontinence: A Phase II Study. Int. Urogyn. J. 1998, 9, 145-150.
8. (e) Andersson, K. E.; Ekman, G.; Henriksson, L.; Ulmsten, U. The effect of midodrine and its active metabolite ST 1059 on the human urethra in vitro and in vivo. Scand. J. Urol. Nephrol. 1983, 17, 261-265.
9. (a) McClellan, K. J.; Wiseman, L. R.; Wilde, M. I. Midodrine. A Review of Its Therapeutic Use in the Management of Orthostatic Hypotension. Drugs Aging 1998, 12, 76-86.
10. (b) Andersson, K. E. Drug therapy for urinary incontinence. Best Pract. Res. Clin. Obstet. Gynaecol. 2000, 14, 291-313.
11. (c) Rackley, R. Treatment of Stress Urinary Incontinence. In Voiding Dysfunction: Diagnosis and Treatment; Appell, R. A., Ed.; Humana Press: Totowa, NJ, 2000; pp 163-184.
12. (a) Hieble, J. P.; Bylund, D. B.; Clarke, D. E.; Eikenburg, D. C.; Langer, S. Z.; Lefkowitz, R. J.; Minneman, K. P.; Ruffolo, R. R. International Union of Pharmacology. X. Recommendation for Nomenclature of Alpha 1-Adrenoceptors: Consensus Update. Pharmacol. Rev. 1995, 47, 267-270.
13. (b) Bylund, D. B.; Eikenberg, D. C.; Hieble, J. P.; Langer, S. Z.; Lefkowitz, R. J.; Minneman, K. P.; Molinoff, P. B.; Ruffolo, R. R.; Trendelenburg, U. International Union of Pharmacology Nomenclature of Adrenoceptors. Pharmacol. Rev. 1994, 46, 121-136.
14. Nasu, K.; Moriyama, N.; Fukasawa, R.; Tsujimoto, G.; Tanaka, T.; Yano, J.; Kawabe, K. Quantification and Distribution of Alpha1-Adrenoceptor Subtype mRNAs in human proximal urethra. Br. J. Pharmacol. 1998, 123, 1289-1293.
15. Brune, M. E.; Katwala, S. P.; Milicic, I.; Buckner, S. A.; Ireland, L. M.; Kerwin, J. F.; Hancock, A. A. Effects of Selective and Nonselective Alpha-1-Adrenoceptor Antagonists on Intraurethral and Arterial Pressures in Intact Conscious Dogs. Pharmacology 1996, 53, 356-368.
16. Hancock, A. A.; Brune, M. E.; Witte, D. G.; Marsh, K. C.; Katwala, S.; Milicic, I.; Ireland, L. M.; Crowell, D.; Meyer, M. D.; Kerwin, J. F. Actions of A-131701, a Novel, Selective Antagonist for Alpha-1A Compared with Alpha-1B Adrenoceptors on Intraurethral and Blood Pressure Responses in Conscious Dogs and a Pharmacodynamic Assessment of in Vivo Prostatic Selectivity. J. Pharmacol. Exp. Ther. 1998, 285, 628-642.
17. Hieble, J. P. Adrenoceptor subclassification: an approach to improved cardiovascular therapeutics. Pharm. Acta Helv. 2000, 74, 163-171.
18. Cavalli, A.; Lattion, A. L.; Hummler, E.; Nenniger, M.; Pedrazzini, T.; Aubert, J. F.; Michel, M. C.; Yang, M.; Lembo, G.; Vecchione, C.; Mostardini, M.; Schmidt, A.; Beermann, F.; Cotecchia, S. Decreased Blood Pressure Response in Mice Deficient of the Alpha1b-Adrenergic Receptor. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 11589-11594.
19. (a) Castillo, E. F.; Lopez, R. M.; Rodriguez-Silverio, J.; Bobadilla, R. A.; Castillo, C. Alpha 1D-Adrenoceptors Contribute to the Neurogenic Vasopressor Response in Pithed Rats. Fundam. Clin. Pharmacol. 1998, 12, 584-589.
20. (b) Villalobos-Molina, R.; Ibarra, M. Vascular Alpha(1D)-Adrenoceptors: Are They Related to Hypertension?. Arch. Med. Res. 1999, 30, 347-352.
21. Tanoue, A.; Koshimizu, T.; Tsujimoto, G. Transgenic studies of alpha(1)-adrenergic receptor subtype function. Life Sci. 2002, 71, 2207-2215.
22. 1 adrenoceptor function in health and disease from transgenic animal studies. Trends Endocrinol. Metab. 2003, 14, 107-113.
23. 1A Receptor Agonist. J. Med. Chem. 1996, 39, 4116-4119.
24. (a) O'Neill, A. B.; Buckner, S. A.; Brune, M. E.; Milicic, I.; Daza, A. V.; Gauvin, D. M.; Altenbach, R. J.; Meyer, M. D.; Williams, M.; Sullivan, J. P.; Brioni, J. D. Pharmacological properties of A-204176, a novel and selective alpha(1A) adrenergic agonist, in in vitro and in vivo models of urethral function. Life Sci. 2001, 70, 181-197.
25. (b) Carroll, W. A.; Altenbach, R. J.; Buckner, S. A.; Brioni, J. D.; Brune, M. E.; Kolasa, T. P.; Meyer, M. D.; Sullivan, J. P. In vitro and in vivo characterization of alpha-1a selective agonists and their utility for stress incontinence. Presented at the 14th Camerino-Noordwijkerhout Symposium "Ongoing Progress in the Receptor Chemistry", Camerino, Italy, September 7-11, 2003.
26. Turner, R. M.; Lindell, S. D.; Ley, S. V. A facile route to imidazol-4-yl anions and their reaction with carbonyl compounds. J. Org. Chem. 1991, 56, 5739-5740.
27. Kirk, K. L. 4-Lithio-1-tritylimidazole as a synthetic intermediate. Synthesis of imidazole-4-carboxaldehyde. J. Heterocycl. Chem. 1985, 22, 57-59.
28. 3H]-prazosin were run as previously described: Knepper, S. M.; Buckner, S. A.; Brune, M. E.; DeBernardis, J. F.; Meyer, M. D.; Hancock, A. A. A-61603, a Potent Alpha 1-Adrenergic Receptor Agonist, Selective for the Alpha 1A Receptor Subtype. J. Pharmacol. Exp. Ther. 1995, 274, 97-103.
29. 3H]-rauwolscine were run as previously described: Hancock, A. A.; Buckner, S. A.; Ireland, L. M.; Knepper, S. M.; Kerwin, J. F., Jr. Actions of terazosin and its enantiomers at subtypes of alpha 1- and alpha 2-adrenoceptors in vitro. J. Recept. Signal Transduction Res. 1995, 15, 863-885.
30. 2C has not been shown to play a role in control of blood pressure.
31. (b) Gavras, I.; Manolis, A. J.; Gavras, H. The alpha(2)-adrenergic receptors in hypertension and heart failure: experimental and clinical studies. J. Hypertens. 2001, 19, 2115-2124.
32. (a) Buckner, S. A.; Milicic, I.; Daza, A. V.; Meyer, M. D.; Altenbach, R. J.; Williams, M.; Sullivan, J. P.; Brioni, J. D. ABT-866, a novel α1A-adrenoceptor agonist with antagonist properties at the α1B- and α1D-adrenoceptor subtypes. Eur. J. Pharmacol. 2002, 449 (1-2), 159-165.
33. (b) Aboud, R.; Shafii, M.; Docherty, J. R. Investigation of the subtypes of alpha 1-adrenoceptor mediating contractions of rat aorta, vas deferens and spleen. Br. J. Pharmacol. 1993, 109, 80-87.
34. 2 = 5.08 ± 0.11, 22% efficacy.
35. Brune, M. E.; O'Neill, A. B.; Gauvin, D. M.; Katwala, S. P.; Altenbach, R. J.; Brioni, J. D.; Hancock, A. A.; Sullivan, J. P. Comparison of alpha1-adrenoceptor agonists in canine urethral pressure profilometry and abdominal leak point pressure models. J. Urol. 2001, 166, 1555-1559.
36. Measurements were made within 1 min of dosing to alleviate any pharmacokinetics effects.
37. 2O (a 15% increase over baseline) and resulted in a significant decrease in leakage episodes from 5 per 24 h to 2 per 24 h.
38. (b) In the in vivo dog model, the baseline pressure measurement is of the catheter balloon pressure and was measured at approximately 400 mmHg. This is not physiologic but due to the elastic forces in the inflated balloon. The IUP measurement was recorded as the net change in pressure above this baseline pressure. From profilometry experiments (data not shown), the measured urethral pressure (the PUCP or proximal urethral closure pressure) that corresponds to the location of the balloon catheter in the in vivo dog model was 4-5 mmHg. Therefore, a 5 mmHg increase in IUP is approximately a 100% increase over physiological baseline urethral pressure.
39. The 20 mmHg increase in MAP was chosen as a consistently measurable response above the noise of the assay. The average baseline MAP values in the anesthetized dogs were about 80 mmHg. Therefore, a 20 mmHg increase in MAP represents approximately a 25% increase over baseline.
40. 2-Adrenoceptors Involving a "Methyl Pocket". J. Med. Chem. 1997, 40, 3014-3024.
41. A boost in potency going from tetralin to indane has been observed previously. See ref 28.
42. Altenbach, R. J.; Khilevich, A.; Meyer, M. D.; Buckner, S. A.; Milicic, I.; Daza, A. V.; Brune, M. E.; O'Neill, A. B.; Gauvin, D. M.; Cain, J. C.; Nakane, M.; Holladay, M. W.; Williams, M.; Brioni, J. D.; Sullivan, J. P. N-[3-(1H-Imidazol-4-ylmethyl)-phenyl]ethanesulfonamide (ABT-866, 1), a Novel α1-Adrenoceptor Ligand with an Enhanced in Vitro and in Vivo Profile Relative to Phenylpropanolamine and Midodrine. J. Med. Chem. 2002, 45, 4395-4397.
43. (a) Schwinn, D. A. The role of alpha(1)-adrenergic receptor subtypes in lower urinary tract symptoms. BJU Int. 2001 88 (Suppl. 2), 27-34.
44. (b) Jarajapu, Y. P. R.; McGrath, J. C.; Hillier, C.; MacDonald, A. The alpha(1)-adrenoceptor profile in human skeletal muscle resistance arteries in critical limb ischaemia. Cardiovasc. Res. 2003, 57, 554-562.
45. (a) Jarajapu, Y. P. R.; Hillier, C.; MacDonald, A. The alpha(1A)-adrenoceptor subtype mediates contraction in rat femoral resistance arteries. Eur. J. Pharmacol. 2001, 422, 127-135.
46. (b) Guilmard, C.; Auguet, M.; Chabrier, P. E. Pharmacological characterization of alpha1-adrenoceptor subtype mediating regulation of arterial pressure and urethral perfusion pressure in the anesthetized rat. J. Auton. Pharmacol. 1996, 16, 197-203.
47. Duka, I.; Gavras, I.; Johns, C.; Handy, D. E.; Gavras, H. Role of the postsynaptic alpha(2)-adrenergic receptor subtypes in catecholamine-induced vasoconstriction. Gen. Pharmacol. 2000, 34, 101-106.
48. (a) Guimaraes, S.; Moura, D. Vascular adrenoceptors: An update. Pharmacol. Rev. 2001, 53, 319-356.
49. (b) Kable, J. W.; Murrin, L. C.; Bylund, D. B. In vivo gene modification elucidates subtype-specific functions of alpha(2)-adrenergic receptors. J. Pharmacol. Exp. Ther. 2000, 293, 1-7.
50. (c) MacDonald, E.; Kobilka, B. K.; Scheinin, M. Gene targeting-homing in on alpha 2-adrenoceptor-subtype function. Trends Pharmacol. Sci. 1997, 18, 211-219.
51. 2 value, slope, and number of compounds/plot (n) are shown in Tables 8 and 9.
52. (a) MacLennan, S. J.; Luong, L. A.; Jasper, J. R.; To, Z. P.; Eglen, R. M. Characterization of alpha 2-adrenoceptors mediating contraction of dog saphenous vein: identity with the human alpha 2A subtype. Br. J. Pharmacol. 1997, 121, 1721-1729.
53. (b) Civantos-Calzada, B.; Aleixandre-de-Artiñano, A. Alpha-adrenoceptor subtypes. Pharmacol. Res. 2001, 44, 195-208.
54. (a) Trendelenburg, A. U.; Limberger, N.; Starke, K. Presynaptic alpha 2-autoreceptors in brain cortex: alpha 2D in the rat and alpha 2A in the rabbit. Naunyn-Schmiedeberg's Arch. Pharmacol. 1993, 348, 35-45.
55. (b) Trendelenburg, A. U.; Wahl, C. A.; Starke, K. Antagonists that differentiate between alpha 2A-and alpha 2D-adrenoceptors. Naunyn-Schmiedeberg's Arch. Pharmacol, 1996, 353, 245-249.
56. (a) Blue, D. R.; Daniels, D. V.; Gever, J. R.; Jett, M. F.; O'Yang, C.; Tang, H. M.; Williams, T. J.; Ford, A. P. D. W. Pharmacological characteristics of Ro 115-1240, a selective alpha1A/1L-adrenoceptor partial agonist: a potential therapy for stress urinary incontinence. BJU Int. 2004, 93, 162-170.
57. (b) Musselman, D. M.; Ford, A. P. D. W.; Gennevois, D. J.; Harbison, M. L.; Laurent, L.; Mokatrin, A. S.; Stoltz, R. R.; Blue, D. R. A randomized crossover study to evaluate Ro 115-1240, a selective alpha1A/1L-adrenoceptor partial agonist in women with stress urinary incontinence. BJU Int. 2004, 93, 78-83.
58. Zhang, M.; Schuster, G. B. Chirochromism-Photochromism by Epimerization: Search for a Liquid Crystal Phototrigger. J. Am. Chem. Soc, 1994, 116, 4852-4857.
59. Schaefer, T.; McKinnon, D. M.; Sebastian, R.; Peeling, J.; Penner, G. H. ; Veregin, R. P. Concerning lone-pair stereospecificity of intramolecular OH hydrogen bonds to oxygen and sulfur in solution. Can. J. Chem. 1987, 65, 908-914.
60. 5-Methanesulfonamido-1-tetralone (4G) was N-benzylated to provide N-benzyl-N-(5-oxo-5,6,7,8-tetrahydronaphthalen-1-yl)-methanesulfonamide (4I) as in example 26 of the following reference: Meyer, M. D.; Hancock, A. A.; Tietje, K.; Sippy, K. B.; Prasad, R.; Stout, D. M.; Arendsen, D. L.; Donner, B. G.; Carroll, W. A. Structure-activity studies for a novel series of N-(arylethyl)-N-(1,2,3,4-tetrahydronaphthalen-1-ylmethyl)-N-methylamines possessing dual 5-HT uptake inhibiting and α2-antagonistic activities. J. Med. Chem. 1997, 40, 1049-1062.
61. King, J. F.; Joe, Y. L.; Lam, J. Y. L.; Ferrazzi, G. Organic sulfur mechanisms. 36. Cyclopropanesulfonyl chloride: its mechanisms of hydrolysis and reactions with tertiary amines in organic media. J. Org. Chem. 1993, 58, 1128-1135.
62. Newman, M. S.; Tuncay, A. Synthesis of 2-fluoro-7,12-dimethylbenz[a]anthracene. J. Org. Chem. 1980, 45, 348-349.
63. Owton, W. M.; Brunavs, M. Synthesis of 6/7-halotetralones. Synth. Commun. 1991, 21, 981-987.
64. Smith, E.; Wraige, E.; Donkin, P.; Rowland, S. Hydrocarbon humps in the marine environment: Synthesis, toxicity, and aqueous solubility of monoaromatic compounds. Environ. Toxicol. Chem. 2001, 20, 2428-2432.
65. Chatterjee, A.; Hazra, B. G. Total synthesis of ring-c aromatic 18-nor steroid. Tetrahedron 1980, 36, 2513-2520.
66. De, B.; DeBernardis, J. F.; Prasad, R. A short synthesis of tetrahydrobenzisoindolines, Synth. Commun. 1988, 18, 481-485.
67. Owton, W. M. Synthesis of 8-fluororhein. J. Chem. Soc., Perkin Trans. 1 1994, 15, 2131-2135,
68. Itoh, K.; Miyake, A.; Tada, N.; Hirata, M.; Oka, Y. Synthesis and β-adrenergic blocking activity of 2-(N-substituted amino)-1,2,3,4-tetrahydronaphthalen-1-ol derivatives. Chem. Pharm. Bull. 1984, 32, 130-151.
69. Hasbun, J. A.; Barker, K. K.; Mertes, M. P. Trimethylammonium phenyl ketones. Actions on the cholinergic receptor and acetylcholinesterase. J. Med. Chem. 1973, 16, 847-849.
70. Gallagher, G.; Lavanchy, P. G.; Wilson, J. W.; Hieble, J. P.; DeMarinis, R. M. 4-[2-(Di-n-propylamino)ethyl]-2(3H)-indolone: a prejunctional dopamine receptor agonist. J. Med. Chem. 1985, 28, 1533-1536.
71. Chakravarti, D.; Dutta, J. Pyrones. I. Attempted oxidation of chromanones with selenium dioxide. J. Indian Chem. Soc. 1939, 16, 639-644.
72. Stanetty, P.; Rodler, I.; Krumpak, B. Synthesis of new N,N,1,1-tetramethylisobenzofuranamines. J. Prakt. Chem. 1993, 335, 17-22.
73. Cliff, M. D.; Pyne, S. G. Synthesis of 4,4′-Biimidazoles. Synthesis 1994, 7, 681-682.
74. 2-adrenoreceptor partial agonist clonidine. J. Med. Chem. 1989, 32, 1627-1630.
75. Rivier, J. E.; Jiang, G.; Porter, J.; Hoeger, C. A.; Craig, A. G.; Corrigan, A.; Vale, W.; Rivier, C. L. Gonadotropin-Releasing Hormone Antagonists: Novel Members of the Azaline B Family. J. Med. Chem. 1995, 38, 2649-2662.